课题基金 / 基金详情

Cardiovascular Disease Mechanisms in HIV Infected and Uninfected Veterans

Cardiovascular Disease Mechanisms in HIV Infected and Uninfected Veterans
感染艾滋病毒和未感染艾滋病毒的退伍军人的心血管疾病机制
批准号:
7890496
负责人:
MATTHEW S FREIBERG
金额:
$87.84万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-25 至 2013-06-30
关键词:
AbbreviationsAbdomenAcquired Immunodeficiency SyndromeAdherenceAdipose tissueAdultAdverse eventAftercareAgeAgingAlberta provinceAlcohol abuseAlcohol consumptionAlcohol or Other Drugs useAlcoholsAreaAtherosclerosisBiological MarkersBloodBlood BanksBlood PressureBody CompositionBody mass indexC-reactive proteinCD4 Lymphocyte CountCalciumCardiacCardiologyCardiovascular DiseasesCardiovascular systemCaringCentral obesityCholesterolClinicalClinical DataClinical TrialsCoagulation ProcessCocaineCohort StudiesComorbidityComputerized Medical RecordCongestive Heart FailureCoronary arteryCoronary heart diseaseDataData CollectionDevelopmentDiseaseDisease OutcomeDyslipidemiasEchocardiographyEducationElectrocardiogramElectron BeamElectron Beam TomographyEnrollmentEnsureEpidemiologyEtiologyEventFibrinolysisFunctional disorderFutureGeneticHIVHIV Envelope Protein gp120HealthHealth SurveysHealth behaviorHepatitis CHepatitis C virusHigh Density LipoproteinsHigh PrevalenceIn VitroIndividualInfectionInflammationInflammatoryInflammatory ResponseInsulin ResistanceInternational Classification of DiseasesJusticeKidney DiseasesLaboratoriesLeftLeft Ventricular Ejection FractionLeft Ventricular HypertrophyLeft ventricular structureLipidsLipoproteinsLow-Density LipoproteinsLung diseasesMeasuresMedicalMedical centerMentorsMetabolicMinorityModelingMyocardial InfarctionMyocardiumNational Heart, Lung, and Blood InstituteObservational StudyOpportunistic InfectionsOutcomeParticipantPatientsPericardial body locationPharmaceutical PreparationsPharmacy facilityPhysical FunctionPlant LeavesPlatelet aggregationPopulationPopulation ControlPositioning AttributePrevalencePreventiveProspective StudiesProtease InhibitorProteinsProtocols documentationPulmonary HypertensionRaceRadiology SpecialtyRegimenResearch PersonnelRetroviridaeReverse Transcriptase InhibitorsRiskRisk FactorsRoleSamplingSiteSmokeSmokingSmooth Muscle MyocytesStructureTestingThromboplastinThrombosisTissuesToxic effectVasospasmVentricularVeteransViral Load resultVirusVirus DiseasesVisceralWomen&aposs HealthWorkX-Ray Computed Tomographyabstractingadjudicatealcohol use disorderantiretroviral therapyaortic valvecardiovascular disorder riskcocaine usecofactorcohortcytokinedesigndrinkingexperiencefasting glucosefitnessfollow-upimprovedinflammatory markermedication compliancemortalityprogramsprospectiveskillssubcutaneoussymposiumtherapy adherencetreatment planning

项目摘要

项目成果

MATTHEW S FREIBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In studies using population controls, HIV infection has been associated with increased risk of cardiovascular disease (CVD). However, this risk may be partially explained by factors other than HIV or its treatment including higher rates of smoking, alcohol abuse, cocaine use, hepatitis C infection and renal disease. Equally important, major mechanisms of CVD among those with HIV likely differ from those without infection because lipid abnormalities occur abruptly--after initiation of combination antiretroviral therapy (CART), and because of inflammatory effects of HIV and HCV, toxic effects of alcohol and vasospasm due to cocaine. The Veterans Aging Cohort Study (VACS) is an ongoing, multicenter, prospective study of 3227 veterans with HIV infection and 3240 age/race/site matched HIV uninfected controls. Teamed with internationally recognized experts in CVD, we propose to supplement the rich clinical data available in this cohort with adjudicated CVD endpoints, and biomarkers and measures of CVD risk including: dyslipidemia, insulin resistance , markers of inflammation, cardiac structural and functional abnormalities, body composition changes, subclinical atherosclerosis, cardiac fitness, and alterations associated with thrombogenesis and fibrinolysis. With these enriched data we will be uniquely positioned to determine whether: 1) HIV infection is an independent risk factor for CVD endpoints and whether HCV, substance use and CART modify the association between HIV and CVD endpoints, 2) biomarkers and measures of CVD risk are increased among those with HIV infection and CART nonadherence, and 3) biomarkers and measures of CVD risk are increased among those with HCV infection and substance use. Importantly, we will adjust for both CART adherence and competing risk, since HIV infected individuals have a substantially higher mortality rate. The large, well characterized, older, predominantly minority patient sample with excellent longitudinal follow up and high prevalence of HCV and substance use, comprehensive pharmacy data, and established access to comprehensive electronic medical records are important leveraged strengths of this application. The strong CVD expertise, established analytic and mentoring skills of the VACS team, and a multi-PI plan incorporating a promising new investigator ensure that this proposal will effectively advance our understanding of CVD outcomes and mechanisms among HIV infected and uninfected individuals. Cardiovascular disease (CVD) is an important health problem among people infected with Human Immunodeficiency Virus (HIV). Whether CVD risk is associated with the HIV virus, treatment for HIV or health problems associated with HIV is not known. Compared with people who are not infected with HIV, HIV infected people have higher rates of smoking, alcohol abuse, cocaine use, and hepatitis C. Thus it is important to compare rates of CVD among those with HIV infection to those without HIV infection who are behaviorally and demographically similar. This proposal will improve our understanding of CVD risk among people infected with HIV. (End of Abstract)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
Administrative, Education, and Analytic Support Core
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
Microbiome, metabolites, and alcohol in HIV to reduce CVD RCT (META HIV CVD RCT)
海外基金